CXCR7抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CXCR7 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using CXCR7 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CXCR7 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using CXCR7 mouse mAb with DAB staining.    

  
  

CXCR7. also known as ACKR3. is a G protein-coupled receptor (GPCR) initially identified as a chemokine receptor binding to CXCL12 and CXCL11. Unlike classical chemokine receptors, CXCR7 lacks G protein-coupled signaling in most contexts but regulates β-arrestin-mediated pathways, influencing cell migration, adhesion, and survival. It shares CXCL12 as a ligand with CXCR4. forming a competitive or cooperative axis critical in development, immune responses, and disease progression. CXCR7 is overexpressed in various cancers, promoting tumor growth, angiogenesis, and metastasis, and is implicated in cardiovascular and inflammatory disorders.

CXCR7 antibodies are essential tools for studying its expression, localization, and functional roles. They enable detection in tissues (via immunohistochemistry) or cells (via flow cytometry) and are used to block ligand binding or receptor internalization in mechanistic studies. Specific monoclonal antibodies (e.g., clones 11G8. 9C4) are validated for targeting extracellular domains, aiding in therapeutic research. Recent efforts focus on developing therapeutic antibodies to disrupt CXCR7-CXCL12 interactions in cancer or modulate its activity in tissue repair. However, challenges remain, including cross-reactivity with related receptors and optimizing specificity for clinical applications. These antibodies also hold diagnostic potential as biomarkers for disease prognosis.